|
| | (3S,4S)-Tofacitinib Basic information |
| Product Name: | (3S,4S)-Tofacitinib | | Synonyms: | 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile;(3S,4S)-4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-beta-oxo-1-piperidinepropanenitrile;(3S,4S)-Tofacitinib;1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3S,4S)-;SS-tofacitinib;Tofacitinib IMpurity A;Tofacitinib IMpurity C Citrate;Tofacitinib Impurity C(3S,4S) | | CAS: | 1092578-47-6 | | MF: | C16H20N6O | | MW: | 312.37 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | (3S,4S)-Tofacitinib Chemical Properties |
| density | 1.296 | | storage temp. | Store at -20°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Powder | | pka | 6.04±0.60(Predicted) |
| | (3S,4S)-Tofacitinib Usage And Synthesis |
| Uses | (3S,4S)-Tofacitinib is an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor(CP-690,550). |
| | (3S,4S)-Tofacitinib Preparation Products And Raw materials |
|